Trade Summary

3 days ago, Congleton Jon, serving as CEO at Mineralys Therapeutics, Inc. (MLYS), sold 15,730 shares at $26.83 per share, for a total transaction value of $421,979.00. Following this transaction, Congleton Jon now holds 689,321 shares of MLYS.

This sale represents a 2.00% decrease in Congleton Jon's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 13, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 15, 2026, 2 days after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.